A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls

Phase 1 Unknown 28 enrolled HK inno.N Corporation

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to compare the pharmacokinetic and safety of tegoprazan following single oral dose in subjects with hepatic impairment versus healthy control.

Timeline

Start: 2020-09-08
Primary completion: 2023-06
Completion: 2023-12

Publications

Kim A, Shin D, Seo Y, Kang D, Min YW, Kim IH, Kim J. Phase I Study to Evaluate the Effect of Hepatic Impairment on Pharmacokinetics and Safety of Tegoprazan, a Potassium Competitive Acid Blocker. Adv Ther. 2025 Mar;42(3):1570-1581. doi: 10.1007/s12325-025-03127-5. Epub 2025 Feb 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tegoprazan	Other / unclassified	50 mg	Oral

Indications

No indication recorded.